Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 14/20 | 0.45 |
| ▸ | NOS3 | P29474 | 12/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | NOS2 | P35228 | 5/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122038 | 0.82 | NOS1 (0.67) | NOS1NOS3SLC6A2NOS2 | |
| SCHEMBL13850013 | 0.77 | NOS3 (0.53) | NOS1NOS3SLC6A2NOS2HTR1D | |
| SCHEMBL1121961 | 0.77 | NOS3 (0.64) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL2936581 | 0.77 | KDM4E (0.54) | NOS1NOS3NOS2 | |
| SCHEMBL2935260 | 0.77 | KDM4E (0.54) | NOS1NOS3NOS2 | |
| SCHEMBL12305088 | 0.76 | NOS3 (0.53) | NOS1NOS3SLC6A2NOS2HTR1D | |
| SCHEMBL12857219 | 0.75 | NOS1 (0.39) | NOS1NOS3SLC6A2NOS2 | |
| SCHEMBL4131599 | 0.74 | NOS3 (0.69) | NOS1NOS3SLC6A2NOS2HTR1D | |
| Hydrochloric Acid SCHEMBL2926467 | 0.74 | NOS3 (0.49) | NOS1NOS3NOS2 | |
| SCHEMBL2940253 | 0.74 | NOS3 (0.49) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010132072-A1 | TREATMENT OR PREVENTION OF MIGRAINE BY DOSING AT AURA | NEURAXON, INC (CA) | 2010-11-18 | — | — | WO | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885SLC6A2 920/4885 |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | NOS1 2/4885NOS3 5/4885SLC6A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.